Evaluation of endothelial dysfunction in women with prolactinoma
Authors' conclusion
Patients with prolactinoma exhibit increased glucose intolerance and impaired endothelial function in the absence of overt global cardiac dysfunction. These alterations appear to be reversible following treatment.
Study context
- Population
- Women with prolactinoma; patients' mean age 26.9 ± 7.4 years, BMI 25.1 ± 5.6 kg/m²
- Participants
- 15 vs 20
- Comparison
- Prolactinoma vs healthy controls; patients before vs after 6 months of cabergoline
- Controlsn = 15reference
- Patientsn = 20
- Outcome
- Flow-mediated dilation (FMD)
- Follow-up
- Baseline
Methodological detailsbefore-after treatment comparison
- Before-after treatment comparison
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
120-min glucose during OGTT · baseline
P = 0.015
| Outcome | Patients | Controls | P value |
|---|---|---|---|
| FMD in patients after cabergoline therapy · after 6 months of treatmentPatients after cabergoline vs Patients at baseline | 13.18 (SD 5.78) % | — not stated in the abstract | P = 0.003 |
— not stated in the abstract
120-min glucose and glucose AUC in patients after treatment vs baseline · after 6 months of treatment
- 120-min glucose significantly reduced after treatment
- P = 0.045
- Glucose AUC significantly reduced after treatment
- P = 0.005
Echocardiographic parameters (systolic and diastolic function) and carotid intima-media thickness (CIMT)
- Similar between groups and unchanged after treatment
Original publication
Evaluation of endothelial dysfunction in women with prolactinoma. Pituitary. Published 22 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →